ImageneBio names Dr. Ben Porter-Brown as chief medical officer

ImageneBio Inc. (NASDAQ: IMA) appointed Dr. Ben Porter-Brown as chief medical officer, the company announced. Porter-Brown will start the role on February 16, 2026.

Porter-Brown brings over 20 years of experience in autoimmune and inflammatory disease drug development. He most recently served as chief medical officer at MoonLake Immunotherapeutics (NASDAQ: MLTX). Previously, he spent more than five years at Kymab Ltd., now a Sanofi company, where he led development of amlitelimab, an anti-OX40 ligand monoclonal antibody, from early human studies through a Phase 2a trial in atopic dermatitis that led to Sanofi's acquisition of Kymab.

At ImageneBio, Porter-Brown will lead the company's clinical organization and oversee the Phase 2b ADAPTIVE trial of IMG-007 in atopic dermatitis. The company plans to expand the trial to include international sites in the UK and Europe.

"Ben's expertise in autoimmune and inflammatory diseases within and beyond medical dermatology, including his previous work on OX40 signaling inhibitors, is an incredible asset for our program," said Kristin Yarema, ImageneBio's chief executive officer.

ImageneBio agreed to grant Porter-Brown 137,000 shares of common stock as an inducement award, comprised of options and restricted stock units. The award will be granted under the company's 2025 Inducement Plan in accordance with Nasdaq listing rules.

IMG-007 is a receptor-targeting, non-depleting anti-OX40 monoclonal antibody. ImageneBio has completed Phase 1b/2a trials of the drug in both atopic dermatitis and alopecia areata and is currently conducting the Phase 2b trial in patients with moderate-to-severe atopic dermatitis.

You May Also Be Interested In

• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• Tenon Medical prices $3M private placement with institutional investor
• Hub Group faces credibility test as Q2 report looms Sept. 1